Stefany Coxe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Interests
Stefany Coxe has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
- David V. Glidden
Department of Epidemiology and Biostatistics, University of California, San Francisco, USA
1 shared publication - Judy Y. Tan
Samuel Oschin Comprehensive Cancer Institute, Cedars Sinai Medical Center, United States
1 shared publication - Matthew A. Spinellii
Division of HIV, Infectious Diseases, and Global Medicine, University of California , San Francisco, California
1 shared publication Monica Gandhi
Division of HIV, Infectious Diseases and Global Medicine, University of California, San Francisco, CA
1 shared publication- Parya Saberi
Division of Prevention Science University of California San Francisco San Francisco California USA
1 shared publication - Renata Buccheri
Vitalant Research Institute San Francisco California USA
1 shared publication
Latest Publications
- Open Access
- 25 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
At-Home Point-of-Care Urine Tenofovir Testing for Adherence Monitoring: Feasibility and Comparison with Adherence Metrics in Dried Blood Spots
Background: Scalable, low-cost strategies for monitoring antiretroviral therapy adherence are increasingly important, particularly in decentralized and telehealth-based care settings. This study assessed both the feasibility and performance of at-home, point-of-care (POC) urine tenofovir (TFV) testing for adherence monitoring, using tenofovir diphosphate (TFV-DP) levels in dried blood spots (DBS) as a pharmacological standard of adherence. Setting: This study was conducted within the LetSync cohort of people with HIV in primary romantic relationships, primarily Black men who have sex with men, across the U.S. Methods: Participants self-collected POC urine TFV testing and DBS samples over five timepoints across eight months. Adequate adherence was defined as TFV-DP ≥4 doses/week in DBS. Generalized estimating equation models evaluated associations between urine TFV results and DBS-based adherence, as well as the probability of sample return over time. Results: Among 86 participants and 341 paired samples, detectable urine TFV was strongly associated with adequate adherence in DBS (aRR = 2.86; 95% CI: 1.37–5.99). The urine POC test demonstrated high sensitivity (97%) and positive predictive value (85%), with lower specificity (31%). Across timepoints, urine samples showed higher return rates compared to DBS (aRR = 1.04; 95% CI: 1.01–1.08). Participants with detectable viral load had lower return rates for DBS compared to urine. Conclusions: At-home POC urine TFV testing is a sensitive and feasible approach for monitoring adherence. Its simplicity and consistently high return rates support its potential as a practical adherence monitoring tool, particularly in settings where VL testing is infrequent or logistically limited.
- 25 September 2026
- Published by Wolters Kluwer Health in JAIDS Journal of Acquired Immune Deficiency Syndromes
Open AccessAt-Home Point-of-Care Urine Tenofovir Testing for Adherence Monitoring: Feasibility and Comparison with Adherence Metrics in Dried Blood Spots
Background: Scalable, low-cost strategies for monitoring antiretroviral therapy adherence are increasingly important, particularly in decentralized and telehealth-based care settings. This study assessed both the feasibility and performance of at-home, point-of-care (POC) urine tenofovir (TFV) testing for adherence monitoring, using tenofovir diphosphate (TFV-DP) levels in dried blood spots (DBS) as a pharmacological standard of adherence. Setting: This study was conducted within the LetSync cohort of people with HIV in primary romantic relationships, primarily Black men who have sex with men, across the U.S. Methods: Participants self-collected POC urine TFV testing and DBS samples over five timepoints across eight months. Adequate adherence was defined as TFV-DP ≥4 doses/week in DBS. Generalized estimating equation models evaluated associations between urine TFV results and DBS-based adherence, as well as the probability of sample return over time. Results: Among 86 participants and 341 paired samples, detectable urine TFV was strongly associated with adequate adherence in DBS (aRR = 2.86; 95% CI: 1.37–5.99). The urine POC test demonstrated high sensitivity (97%) and positive predictive value (85%), with lower specificity (31%). Across timepoints, urine samples showed higher return rates compared to DBS (aRR = 1.04; 95% CI: 1.01–1.08). Participants with detectable viral load had lower return rates for DBS compared to urine. Conclusions: At-home POC urine TFV testing is a sensitive and feasible approach for monitoring adherence. Its simplicity and consistently high return rates support its potential as a practical adherence monitoring tool, particularly in settings where VL testing is infrequent or logistically limited.